David C. Marek - 15 Apr 2022 Form 4 Insider Report for Myovant Sciences Ltd.

Role: Principal Executive Officer, Director
Signature: /s/ Matthew Lang, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 15 Apr 2022
Net transactions value: $0
Form type: 4
Filing time: 19 Apr 2022, 16:46:56 UTC
Previous filing: 21 Jan 2022
Next filing: 21 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MYOV	Common Shares	Award	$0	+134,567	+40%	$0.000000	472,550	15 Apr 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MYOV	Stock Option (Right to Buy)	Award	$0	+204,808		$0.000000	204,808	15 Apr 2022	Common Shares	204,808	$11.33	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2023, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
F2	1/4 of the common shares underlying this option vest on April 15, 2023, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.